Cargando…

Safety, tolerability and pharmacokinetics of emodepside, a potential novel treatment for onchocerciasis (river blindness), in healthy male subjects

AIMS: Emodepside is an anthelmintic, originally developed for veterinary use. We investigated in healthy subjects the safety, and pharmacokinetics of a liquid service formulation (LSF) and immediate release (IR) tablet of emodepside in 2 randomised, parallel‐group, placebo‐controlled, Phase I studie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gillon, Jean‐Yves, Dennison, Jeremy, van den Berg, Frans, Delhomme, Sophie, Dequatre Cheeseman, Karen, Peña Rossi, Claudia, Strub Wourgaft, Nathalie, Specht, Sabine, Pedrique, Belén, Monnot, Frédéric, Skrabs, Susanne, Rodriguez, Maria‐Luisa, Stass, Heino
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518114/ https://www.ncbi.nlm.nih.gov/pubmed/33759250 http://dx.doi.org/10.1111/bcp.14816

Ejemplares similares

Drug development for the treatment of onchocerciasis: Population pharmacokinetic and adverse events modeling of emodepside
por: Assmus, Frauke, et al.
Publicado: (2022)

Development of emodepside as a possible adulticidal treatment for human onchocerciasis—The fruit of a successful industrial–academic collaboration
por: Krücken, Jürgen, et al.
Publicado: (2021)

Emodepside targets SLO-1 channels of Onchocerca ochengi and induces broad anthelmintic effects in a bovine model of onchocerciasis
por: Bah, Germanus S., et al.
Publicado: (2021)

Evaluation of the in vitro susceptibility of various filarial nematodes to emodepside
por: Hübner, Marc P., et al.
Publicado: (2021)

The burden of skin disease and eye disease due to onchocerciasis in countries formerly under the African Programme for Onchocerciasis Control mandate for 1990, 2020, and 2030
por: Vinkeles Melchers, Natalie V. S., et al.
Publicado: (2021)

Supporting Drug Development for Neglected Tropical Diseases Using Mathematical Modeling
por: Walker, Martin, et al.
Publicado: (2021)

From river blindness to river epilepsy: Implications for onchocerciasis elimination programmes
por: Colebunders, Robert, et al.
Publicado: (2019)

Projected Number of People With Onchocerciasis–Loiasis Coinfection in Africa, 1995 to 2025
por: Vinkeles Melchers, Natalie V S, et al.
Publicado: (2020)

Report of the first international workshop on onchocerciasis-associated epilepsy
por: Colebunders, Robert, et al.
Publicado: (2018)

Safety of concurrent treatment of cats with fluralaner and emodepsid–praziquantel
por: Walther, Feli M., et al.
Publicado: (2016)

Natural variation in Caenorhabditis elegans responses to the anthelmintic emodepside
por: Wit, Janneke, et al.
Publicado: (2021)

Efficacy of two topical combinations containing emodepside plus praziquantel, and emodepside plus praziquantel plus tigolaner, for the treatment of troglostrongylosis in experimentally infected cats
por: Traversa, Donato, et al.
Publicado: (2022)

How does onchocerciasis-related skin and eye disease in Africa depend on cumulative exposure to infection and mass treatment?
por: Vinkeles Melchers, Natalie V. S., et al.
Publicado: (2021)

Elimination of lymphatic filariasis in South East Asia
por: Specht, Sabine, et al.
Publicado: (2019)

Designing antifilarial drug trials using clinical trial simulators
por: Walker, Martin, et al.
Publicado: (2020)

Erratum to: Safety of concurrent treatment of cats with fluralaner and emodepsid-praziquantel
por: Walther, Feli M., et al.
Publicado: (2016)

Worms take to the slo lane: a perspective on the mode of action of emodepside
por: Holden-Dye, Lindy, et al.
Publicado: (2012)

Evaluation of emodepside in laboratory models of human intestinal nematode and schistosome infections
por: Karpstein, Tanja, et al.
Publicado: (2019)

Onchocerciasis drug development: from preclinical models to humans
por: Ngwewondo, Adela, et al.
Publicado: (2021)

Financial and Economic Costs of the Elimination and Eradication of Onchocerciasis (River Blindness) in Africa
por: Kim, Young Eun, et al.
Publicado: (2015)

Modelling the health and economic impacts of the elimination of river blindness (onchocerciasis) in Africa
por: Kim, Young Eun, et al.
Publicado: (2017)

A Physiologically-Based Pharmacokinetic Model to Describe Ciprofloxacin Pharmacokinetics Over the Entire Span of Life
por: Schlender, Jan-Frederik, et al.
Publicado: (2018)

Perception and Attitude of People Toward Onchocerciasis (River Blindness) in South Western Nigeria
por: Adeoye, A. O., et al.
Publicado: (2010)

Plasma pharmacokinetics of tigolaner, emodepside, and praziquantel following topical administration of a combination product (Felpreva®) and of intravenous administration of the individual active ingredients in cats
por: Mencke, Norbert, et al.
Publicado: (2023)

Onchocerciasis
Publicado: (1911)

Elimination of onchocerciasis from Colombia: first proof of concept of river blindness elimination in the world
por: Nicholls, Rubén Santiago, et al.
Publicado: (2018)

Diethylcarbamazine mediated potentiation of emodepside induced paralysis requires TRP-2 in adult Brugia malayi
por: Kashyap, Sudhanva S., et al.
Publicado: (2022)

Application of Physiologically‐Based and Population Pharmacokinetic Modeling for Dose Finding and Confirmation During the Pediatric Development of Moxifloxacin
por: Willmann, Stefan, et al.
Publicado: (2019)

2) Onchocerciasis
por: Tada, Isao
Publicado: (2015)

3) Onchocerciasis
por: Tada, Isao
Publicado: (2015)

Effect of food on the pharmacokinetics of zoliflodacin granules for oral suspension: Phase I open‐label randomized cross‐over study in healthy subjects
por: Luckey, Alison, et al.
Publicado: (2023)

Habitat preference of blackflies in Omo Gibe river basin (southwest Ethiopia): Implications for onchocerciasis elimination and control
por: Olkeba, Beekam Kebede, et al.
Publicado: (2022)

Can a single dose of Modified Vaccinia Ankara-Bavarian Nordic vaccine protect against mpox?
por: Ogoina, Dimie, et al.
Publicado: (2023)

Navigating the way to onchocerciasis elimination: the feasibility and affordability of Onchocerciasis Elimination Mapping
por: Hamill, Louise, et al.
Publicado: (2022)

Information for onchocerciasis control
por: Hopkins, Adrian
Publicado: (2010)

Onchocerciasis: the beginning of the end?
por: Hopkins, Adrian
Publicado: (2019)

Characterization of the Ca(2+)-Gated and Voltage-Dependent K(+)-Channel Slo-1 of Nematodes and Its Interaction with Emodepside
por: Kulke, Daniel, et al.
Publicado: (2014)

Diethylcarbamazine Increases Activation of Voltage-Activated Potassium (SLO-1) Currents in Ascaris suum and Potentiates Effects of Emodepside
por: Buxton, Samuel K., et al.
Publicado: (2014)

Pilot study evaluating the efficacy of a topical formulation containing emodepside and praziquantel in the treatment of natural feline troglostrongylosis
por: Traversa, Donato, et al.
Publicado: (2019)

Gastrointestinal Parasite Infection in Cats in Daegu, Republic of Korea, and Efficacy of Treatment Using Topical Emodepside/Praziquantel Formulation
por: Lee, Seung-Hun, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_fnrljorjh2d05b74blt8le1a3k